BioPharmaSpec expanding into Asia with new business development teams

Scientists can meet with BioPharmaSpec experts at BioPharma Asia to discuss characterization strategies for accelerating their biosimilar development.

BioPharmaSpec’s new business development teams will offer scientists in Asia access to technical experts, who will detail how the company’s unrivalled expertise in mass spectrometry can be used to characterize critical features of biologics, providing them with a competitive edge for their biosimilar development.

Having already established relationships with major Asian firms developing biosimilars for the global market, BioPharmaSpec operates to robust quality standards, allowing full traceability without the associated costs of a Good Manufacturing Practice (GMP) system (which is not required for the early-stage characterization and comparability of biosimilars). The company also provides Asian biopharma firms with a clear understanding of what types of analysis and documentation are necessary to meet the stringent requirements of European and US regulators.

To support the expansion into Asia, CEO Dr Andrew J. Reason is presenting at BioPharma Asia in Singapore on 22–24 March, 2016 with a session entitled “Structural Characterization of Monoclonal Antibodies and Antibody Drug Conjugates”. The presentation will focus on how mass spectrometry and other techniques are employed to characterize biopharmaceutical products and will present several interesting case studies, including examples of biosimilar development.

“The structural characterization of biopharmaceutical products is a broad and complicated process and a wide variety of techniques are involved in providing full characterization information. For these reasons, I believe that our industry values proven technical expertise and product experience when selecting a CRO partner, especially when important decisions relating to comparability or biosimilarity are to be made”, commented BioPharmaSpec Founder and CEO Dr Andrew J. Reason. “I look forward to presenting on how BioPharmaSpec scientists use technical and instrumentation expertise built up over 35 years to provide quality analytical data that our clients can rely on.”